ErbB2/Her2 anticorps (pTyr877)
Aperçu rapide pour ErbB2/Her2 anticorps (pTyr877) (ABIN318038)
Antigène
Voir toutes ErbB2/Her2 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- pTyr877
-
Specificité
- This antibody detects endogenous levels of HER2 protein. (region surrounding Tyr877)
-
Réactivité croisée (Details)
-
Species reactivity (expected):Mouse and Rat.
Species reactivity (tested):Human. -
Purification
- Affinity Chromatography using epitope-specific immunogen.
-
-
-
-
Indications d'application
-
ELISA: 1/10000-1/20000. Western Blot: 1/500-1/1000. Immunohistochemistry: 1/50-1/200. Immunoprecipitation: 1/50-1/200.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Restrictions
- For Research Use only
-
-
-
Concentration
- 1.0 mg/mL
-
Buffer
- Phosphate buffered saline (PBS), pH ~7.2, 0.05 % Sodium Azide
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Conseil sur la manipulation
- Avoid repeated freezing and thawing.
-
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))
-
Autre désignation
- CD340 / ERBB2 / HER2
-
Sujet
- The EGF receptor family comprises several related receptor tyrosine kinases that are frequently overexpressed in a variety of carcinomas. Members of this receptor family include EGFR (HER1), Neu (ErbB-2, HER2), ErbB-3 (HER3), and ErbB-4 (HER4), which form either homodimers or heterodimers upon ligand binding. Neu, a 185 kDa glycoprotein, undergoes transactivation upon heterodimerizaion with other EGF receptor family members. Neu heterodimerization with ErbB-3 recruits heregulin, which induces phosphoinositide (PI) 3-kinase activation. Activation of Neu potentiates tumor cell motility and protease secretion and invasion, and also modulates cell cycle checkpoint function, DNA repair and apoptotic responses. Amplification and/or overexpression of Neu occurs in 20-30 % of breast carcinomas. Measurement of increased Neu expression can be a predictor of disease prognosis. Neu may also prove to bea promising target for therapeutic agents.Synonyms: HER-2, MNL19, NEU, NEU proto-oncogene, NGL, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, c-erbB-2, p185erbB2
-
Poids moléculaire
- approx. 138, 185 kDa
-
ID gène
- 2064
-
NCBI Accession
- NP_001005862
-
UniProt
- P04626
-
Pathways
- Signalisation RTK, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Skeletal Muscle Fiber Development
Antigène
-